ASKA Pharmaceutical Holdings Co.,Ltd. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

Overview of Performance

This period's results expanded with net sales of 35,626 million yen (YoY +1.1%), operating income of 2,740 million yen (YoY +3.5%), and ordinary income of 2,862 million yen (YoY +8.5%). Interim net income was 2,006 million yen (YoY -9.6%). By segment, Pharmaceuticals, Animal Health, and Overseas operations contributed to performance. Net assets amounted to 80,225 million yen, raising the equity ratio to 65.69%. Cash decreased but the financial structure remains stable. Research and development expenditures continue. Financial position shows total assets of 111,882 million yen and liabilities of 31,656 million yen.

Outlook and Key Notes

There is no change to the consolidated forecasts for the fiscal year ending March 2027. An earnings briefing will be held for institutional investors and analysts. Dividend policy for the fiscal year assumes 27 yen at the end of the first quarter, 32 yen at the end of the second quarter, and 33 yen at the end of the third quarter, totaling 65 yen for the year. Major segments focus on internal medicine, obstetrics & gynecology, and urology. The Company will continue to monitor the effects of drug price revisions and rising raw material costs. Multiple clinical development programs including AKP-022 are in progress.